iPSpine H2020

iPSpine H2020

Chronic lower back pain (LBP) is the leading cause of disability and morbidity worldwide. More than 700 million people globally of all ages are affected each year. LBP is a major cause of reduced activity and work absence, and imposes an economic burden of nearly ~€240 billion every year in the EU. The H2020 project iPSpine aims to investigate and develop a new therapy for LBP using induced pluripotent stem cells (iPSCs). The project will develop an advanced therapy using iPS-technology and smart biomaterials that will be translated from laboratory models into a clinically relevant animal model. By the end of the project, the therapy should be ready for advancement to the first human clinical trial.

H2020 Project 825925